thebench.bio #1 Ecosystem for the Bio-Tech Industry

Software Daily Summary

Software Daily Summary: What Happened on November 19, 2026

NetraAI identified depression-trial subgroups later seen in two Phase III trials, Geraci says

Interviews explored AI analysis of clinical-trial data and potential uses in pharmaceutical care. Commentary on antimicrobial resistance called trustworthy data a prerequisite for AI.

  • Updated
  • Read from 3 articles, 2 publications
  • P P

Today in brief

Joe Geraci said NetraAI found responder subgroups in data from a failed depression trial, with those findings later replicated in two Phase III trials.1 Infinitus CEO Ankit Jain said agentic AI could give physicians more tools for choosing medicines and helping patients access and afford them.2

NetraMark says AI found depression-trial responder groups later seen in Phase III

NetraMark co-founder Joe Geraci said NetraAI identified responder subgroups in a failed depression trial, and that the findings were later replicated in two Phase III trials.1 He said the system analyzes Phase II data to find patient groups whose response may be obscured by results across the full trial population.1

Geraci said NetraAI can estimate patients’ likelihood of responding to placebo as well as to a drug.1 He called transparency, including clear explanations of model recommendations and parameters, central to using AI in clinical trials.1

Geraci said analysis of Answer ALS data separated patients by disease progression and whether symptoms began in the limbs or bulbar region, then found further patterns within those groups.1 He said NetraAI can identify patients it can model and those it cannot, rather than assigning every patient to a category.1

Infinitus CEO says agentic AI could change how pharma supports care

Infinitus founder and CEO Ankit Jain said agentic AI could give physicians and field teams more tools and communication options, potentially changing pharmaceutical companies’ commercial model.2 He said the growing number of specialty medicines and coverage guidelines is making questions about access, adherence and affordability more complex.2

Jain said the technology could help physicians choose medicines and help patients obtain and afford them.2 He argued that providers should have access to resources from across the healthcare system when prescribing, and said agentic models should deliver benefits beyond productivity.2

Also worth knowing

  • P

    Nicole Raleigh’s commentary framed trustworthy data as a prerequisite for using AI against antimicrobial resistance.3